Celltrion fell to the 170,000-won range, weighed down by short-term supply and demand pressures despite favorable target prices from the securities industry.

As of the morning of the 6th, Celltrion is trading at 175,100 won, down more than 4.6% from the previous trading day. Profit-taking sell orders following the recent rally have emerged, and volatility across the broader biotech sector has expanded, leading to continued share price declines.

The medium- to long-term outlook from the securities industry remains positive. Hyundai Motor Securities analyst Kim Hyun-seok maintained a "Buy" rating and a target price of 270,000 won for Celltrion. This is the same level as the previous target price presented on May 7, 2026. After raising the target price from 230,000 won to 270,000 won on July 17 of last year, Hyundai Motor Securities maintained it again this time, holding to a positive view on the company's valuation.

Favorable earnings factors cited include an increasing share of high-margin biosimilar products, improved cost structure, and enhanced production efficiency. The expansion of new product sales and profitability improvements are expected to support medium- to long-term performance. Expectations for entering the seasonal peak season in the second half and expanding sales in the U.S. market also continue to be felt in the market.

However, some point out that in the short term, changes in supply and demand in the domestic stock market, investor sentiment in the biotech sector, and foreign trading trends could amplify share price volatility. The market is focusing on the possibility that a volatile market environment will persist for the time being as expectations for earnings improvements intersect with short-term supply and demand pressures.

[This article was written with the assistance of AI. This article is not intended to recommend investment, and the final decision and responsibility for investing lie with the investor.]